14-21090844-C-T
Position:
Variant summary
Our verdict is Likely benign. Variant got -6 ACMG points: 0P and 6B. BP4_ModerateBS2
The NM_016423.3(ZNF219):c.1861G>A(p.Gly621Ser) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0000244 in 1,555,546 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Uncertain significance (★).
Frequency
Genomes: 𝑓 0.00011 ( 0 hom., cov: 33)
Exomes 𝑓: 0.000015 ( 0 hom. )
Consequence
ZNF219
NM_016423.3 missense
NM_016423.3 missense
Scores
1
4
14
Clinical Significance
Conservation
PhyloP100: 1.16
Genes affected
ZNF219 (HGNC:13011): (zinc finger protein 219) This gene is a member of the Kruppel-like zinc finger gene family. The encoded protein functions as a transcriptional repressor of the high mobility group nucleosome binding domain 1 protein, which is associated with transcriptionally active chromatin. [provided by RefSeq, Apr 2017]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Likely_benign. Variant got -6 ACMG points.
BP4
Computational evidence support a benign effect (MetaRNN=0.15283358).
BS2
High AC in GnomAd4 at 17 AD gene.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
ZNF219 | NM_016423.3 | c.1861G>A | p.Gly621Ser | missense_variant | 5/5 | ENST00000360947.8 | NP_057507.2 | |
ZNF219 | NM_001101672.2 | c.1861G>A | p.Gly621Ser | missense_variant | 5/5 | NP_001095142.1 | ||
ZNF219 | NM_001102454.2 | c.1861G>A | p.Gly621Ser | missense_variant | 5/5 | NP_001095924.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
ZNF219 | ENST00000360947.8 | c.1861G>A | p.Gly621Ser | missense_variant | 5/5 | 1 | NM_016423.3 | ENSP00000354206.3 | ||
ZNF219 | ENST00000421093.6 | c.1861G>A | p.Gly621Ser | missense_variant | 5/5 | 1 | ENSP00000392401.2 | |||
ZNF219 | ENST00000451119.6 | c.1861G>A | p.Gly621Ser | missense_variant | 5/5 | 5 | ENSP00000388558.2 |
Frequencies
GnomAD3 genomes AF: 0.000112 AC: 17AN: 152226Hom.: 0 Cov.: 33
GnomAD3 genomes
AF:
AC:
17
AN:
152226
Hom.:
Cov.:
33
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.0000270 AC: 4AN: 148418Hom.: 0 AF XY: 0.00 AC XY: 0AN XY: 80530
GnomAD3 exomes
AF:
AC:
4
AN:
148418
Hom.:
AF XY:
AC XY:
0
AN XY:
80530
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.0000150 AC: 21AN: 1403320Hom.: 0 Cov.: 32 AF XY: 0.00000577 AC XY: 4AN XY: 692790
GnomAD4 exome
AF:
AC:
21
AN:
1403320
Hom.:
Cov.:
32
AF XY:
AC XY:
4
AN XY:
692790
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.000112 AC: 17AN: 152226Hom.: 0 Cov.: 33 AF XY: 0.000188 AC XY: 14AN XY: 74360
GnomAD4 genome
AF:
AC:
17
AN:
152226
Hom.:
Cov.:
33
AF XY:
AC XY:
14
AN XY:
74360
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Bravo
AF:
ClinVar
Significance: Uncertain significance
Submissions summary: Uncertain:1
Revision: criteria provided, single submitter
LINK: link
Submissions by phenotype
not specified Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Ambry Genetics | Jun 17, 2024 | The c.1861G>A (p.G621S) alteration is located in exon 5 (coding exon 4) of the ZNF219 gene. This alteration results from a G to A substitution at nucleotide position 1861, causing the glycine (G) at amino acid position 621 to be replaced by a serine (S). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
AlphaMissense
Benign
BayesDel_addAF
Benign
T
BayesDel_noAF
Benign
CADD
Uncertain
DANN
Uncertain
DEOGEN2
Benign
T;T;T
Eigen
Uncertain
Eigen_PC
Uncertain
FATHMM_MKL
Uncertain
D
LIST_S2
Benign
.;.;T
M_CAP
Benign
T
MetaRNN
Benign
T;T;T
MetaSVM
Benign
T
MutationAssessor
Benign
N;N;N
PrimateAI
Pathogenic
D
PROVEAN
Benign
N;N;N
REVEL
Benign
Sift
Benign
T;T;T
Sift4G
Benign
T;T;T
Polyphen
D;D;D
Vest4
MutPred
Gain of phosphorylation at G621 (P = 0.0108);Gain of phosphorylation at G621 (P = 0.0108);Gain of phosphorylation at G621 (P = 0.0108);
MVP
MPC
ClinPred
T
GERP RS
Varity_R
gMVP
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at